BioMarin Pharmaceutical Competitors

Amgen (NASDAQ:AMGN) and BioMarin Pharmaceutical (NASDAQ:BMRN) are both large-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, institutional ownership, risk and dividends.

Volatility and Risk

Amgen has a beta of 0.81, indicating that its stock price is 19% less volatile than the S&P 500. Comparatively, BioMarin Pharmaceutical has a beta of 0.69, indicating that its stock price is 31% less volatile than the S&P 500.

Profitability

This table compares Amgen and BioMarin Pharmaceutical's net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of recent recommendations for Amgen and BioMarin Pharmaceutical, as provided by MarketBeat.

Amgen presently has a consensus price target of $254.08, indicating a potential upside of 13.02%. BioMarin Pharmaceutical has a consensus price target of $119.6667, indicating a potential upside of 48.84%. Given BioMarin Pharmaceutical's stronger consensus rating and higher possible upside, analysts plainly believe BioMarin Pharmaceutical is more favorable than Amgen.

Earnings & Valuation

This table compares Amgen and BioMarin Pharmaceutical's gross revenue, earnings per share (EPS) and valuation.

Amgen has higher revenue and earnings than BioMarin Pharmaceutical. Amgen is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

71.7% of Amgen shares are held by institutional investors. Comparatively, 89.4% of BioMarin Pharmaceutical shares are held by institutional investors. 0.4% of Amgen shares are held by insiders. Comparatively, 2.2% of BioMarin Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Gilead Sciences (NASDAQ:GILD) and BioMarin Pharmaceutical (NASDAQ:BMRN) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, dividends and risk.

Institutional & Insider Ownership

77.9% of Gilead Sciences shares are owned by institutional investors. Comparatively, 89.4% of BioMarin Pharmaceutical shares are owned by institutional investors. 0.1% of Gilead Sciences shares are owned by company insiders. Comparatively, 2.2% of BioMarin Pharmaceutical shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Gilead Sciences and BioMarin Pharmaceutical's top-line revenue, earnings per share and valuation.

Gilead Sciences has higher revenue and earnings than BioMarin Pharmaceutical. Gilead Sciences is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Gilead Sciences and BioMarin Pharmaceutical's net margins, return on equity and return on assets.

Volatility and Risk

Gilead Sciences has a beta of 0.53, suggesting that its stock price is 47% less volatile than the S&P 500. Comparatively, BioMarin Pharmaceutical has a beta of 0.69, suggesting that its stock price is 31% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Gilead Sciences and BioMarin Pharmaceutical, as provided by MarketBeat.

Gilead Sciences currently has a consensus price target of $76.1538, indicating a potential upside of 26.86%. BioMarin Pharmaceutical has a consensus price target of $119.6667, indicating a potential upside of 48.84%. Given BioMarin Pharmaceutical's stronger consensus rating and higher probable upside, analysts clearly believe BioMarin Pharmaceutical is more favorable than Gilead Sciences.

Summary

BioMarin Pharmaceutical beats Gilead Sciences on 8 of the 14 factors compared between the two stocks.

Vertex Pharmaceuticals (NASDAQ:VRTX) and BioMarin Pharmaceutical (NASDAQ:BMRN) are both large-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, profitability, earnings, valuation, institutional ownership and analyst recommendations.

Analyst Ratings

This is a summary of recent ratings and price targets for Vertex Pharmaceuticals and BioMarin Pharmaceutical, as provided by MarketBeat.

Vertex Pharmaceuticals currently has a consensus price target of $290.5862, indicating a potential upside of 28.18%. BioMarin Pharmaceutical has a consensus price target of $119.6667, indicating a potential upside of 48.84%. Given BioMarin Pharmaceutical's higher possible upside, analysts plainly believe BioMarin Pharmaceutical is more favorable than Vertex Pharmaceuticals.

Risk and Volatility

Vertex Pharmaceuticals has a beta of 0.79, indicating that its share price is 21% less volatile than the S&P 500. Comparatively, BioMarin Pharmaceutical has a beta of 0.69, indicating that its share price is 31% less volatile than the S&P 500.

Valuation & Earnings

This table compares Vertex Pharmaceuticals and BioMarin Pharmaceutical's revenue, earnings per share (EPS) and valuation.

Vertex Pharmaceuticals has higher revenue and earnings than BioMarin Pharmaceutical. Vertex Pharmaceuticals is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Vertex Pharmaceuticals and BioMarin Pharmaceutical's net margins, return on equity and return on assets.

Insider and Institutional Ownership

92.2% of Vertex Pharmaceuticals shares are held by institutional investors. Comparatively, 89.4% of BioMarin Pharmaceutical shares are held by institutional investors. 0.7% of Vertex Pharmaceuticals shares are held by company insiders. Comparatively, 2.2% of BioMarin Pharmaceutical shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Vertex Pharmaceuticals beats BioMarin Pharmaceutical on 12 of the 15 factors compared between the two stocks.

BioMarin Pharmaceutical (NASDAQ:BMRN) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, analyst recommendations, earnings, profitability, valuation and dividends.

Analyst Recommendations

This is a summary of current ratings and target prices for BioMarin Pharmaceutical and Regeneron Pharmaceuticals, as provided by MarketBeat.

BioMarin Pharmaceutical currently has a consensus target price of $119.6667, suggesting a potential upside of 48.84%. Regeneron Pharmaceuticals has a consensus target price of $628.52, suggesting a potential upside of 22.27%. Given BioMarin Pharmaceutical's higher probable upside, research analysts plainly believe BioMarin Pharmaceutical is more favorable than Regeneron Pharmaceuticals.

Profitability

This table compares BioMarin Pharmaceutical and Regeneron Pharmaceuticals' net margins, return on equity and return on assets.

Insider & Institutional Ownership

89.4% of BioMarin Pharmaceutical shares are owned by institutional investors. Comparatively, 85.9% of Regeneron Pharmaceuticals shares are owned by institutional investors. 2.2% of BioMarin Pharmaceutical shares are owned by insiders. Comparatively, 11.8% of Regeneron Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Earnings and Valuation

This table compares BioMarin Pharmaceutical and Regeneron Pharmaceuticals' top-line revenue, earnings per share and valuation.

Regeneron Pharmaceuticals has higher revenue and earnings than BioMarin Pharmaceutical. Regeneron Pharmaceuticals is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

BioMarin Pharmaceutical has a beta of 0.69, indicating that its share price is 31% less volatile than the S&P 500. Comparatively, Regeneron Pharmaceuticals has a beta of 0.51, indicating that its share price is 49% less volatile than the S&P 500.

Summary

Regeneron Pharmaceuticals beats BioMarin Pharmaceutical on 9 of the 14 factors compared between the two stocks.

BioMarin Pharmaceutical (NASDAQ:BMRN) and Biogen (NASDAQ:BIIB) are both large-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, risk, dividends, institutional ownership, profitability and analyst recommendations.

Institutional & Insider Ownership

89.4% of BioMarin Pharmaceutical shares are held by institutional investors. Comparatively, 78.9% of Biogen shares are held by institutional investors. 2.2% of BioMarin Pharmaceutical shares are held by insiders. Comparatively, 0.5% of Biogen shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Risk & Volatility

BioMarin Pharmaceutical has a beta of 0.69, meaning that its stock price is 31% less volatile than the S&P 500. Comparatively, Biogen has a beta of 0.61, meaning that its stock price is 39% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current recommendations and price targets for BioMarin Pharmaceutical and Biogen, as provided by MarketBeat.

BioMarin Pharmaceutical currently has a consensus target price of $119.6667, suggesting a potential upside of 48.84%. Biogen has a consensus target price of $305.9032, suggesting a potential upside of 25.48%. Given BioMarin Pharmaceutical's stronger consensus rating and higher probable upside, equities analysts clearly believe BioMarin Pharmaceutical is more favorable than Biogen.

Profitability

This table compares BioMarin Pharmaceutical and Biogen's net margins, return on equity and return on assets.

Valuation and Earnings

This table compares BioMarin Pharmaceutical and Biogen's revenue, earnings per share (EPS) and valuation.

Biogen has higher revenue and earnings than BioMarin Pharmaceutical. Biogen is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Summary

BioMarin Pharmaceutical beats Biogen on 8 of the 13 factors compared between the two stocks.

Seagen (NASDAQ:SGEN) and BioMarin Pharmaceutical (NASDAQ:BMRN) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, dividends, profitability, analyst recommendations, valuation, risk and institutional ownership.

Risk & Volatility

Seagen has a beta of 1.13, indicating that its stock price is 13% more volatile than the S&P 500. Comparatively, BioMarin Pharmaceutical has a beta of 0.69, indicating that its stock price is 31% less volatile than the S&P 500.

Profitability

This table compares Seagen and BioMarin Pharmaceutical's net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Seagen and BioMarin Pharmaceutical's revenue, earnings per share (EPS) and valuation.

BioMarin Pharmaceutical has higher revenue and earnings than Seagen. Seagen is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Seagen and BioMarin Pharmaceutical, as provided by MarketBeat.com.

Seagen currently has a consensus price target of $176.75, indicating a potential upside of 4.51%. BioMarin Pharmaceutical has a consensus price target of $119.6667, indicating a potential upside of 48.84%. Given BioMarin Pharmaceutical's higher possible upside, analysts clearly believe BioMarin Pharmaceutical is more favorable than Seagen.

Insider & Institutional Ownership

92.0% of Seagen shares are held by institutional investors. Comparatively, 89.4% of BioMarin Pharmaceutical shares are held by institutional investors. 31.1% of Seagen shares are held by company insiders. Comparatively, 2.2% of BioMarin Pharmaceutical shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

BioMarin Pharmaceutical beats Seagen on 9 of the 15 factors compared between the two stocks.